Objectives: Determining the in vitro susceptibility to 11 antibiotics of Francisella tularensis subsp. holarctica strains belonging to the phylogenetic group B.13, from different areas of Hungary.
Introduction
Francisella tularensis, a fastidious, Gram-negative bacterium, is the causative agent of the highly contagious zoonotic disease, tularaemia, which has gained increased attention during the last decade due to the possibility of its use in bioterrorism events. 1 As F. tularensis subsp. holarctica is prevalent all over the Northern hemisphere, it is endemic in Europe, including Hungary, where reported human cases have numbered between 5 and 200 annually for the last decade. 2 Close contact with European brown hares (Lepus europaeus) or tick bite were most frequently reported in the anamneses of these cases. 2 Tularaemia may occur in six well-recognized clinical forms in humans: ulceroglandular, glandular, oculoglandular, oropharyngeal, pneumonic and typhoid (or septicaemic) tularaemia. 1 The antibiotics of choice in the treatment of tularaemia are aminoglycosides, quinolones, chloramphenicol or tetracyclines, bearing in mind the side effects and probability of relapse.
1 A general picture of the antibiotic susceptibility of European F. tularensis subsp. holarctica strains can be obtained from several current and previous studies. 3 -9 The aim of this study was to characterize the in vitro antimicrobial susceptibility profile of 29 selected Hungarian F. tularensis subsp. holarctica strains to 11 antibiotics (erythromycin, streptomycin, gentamicin, ciprofloxacin, levofloxacin, tetracycline, doxycycline, tigecycline, rifampicin, linezolid and chloramphenicol) that could potentially be used in clinical therapy.
Materials and methods

F. tularensis isolation and characterization
Samples were collected between 2003 and 2010 for F. tularensis isolation from seropositive European brown hares shot during hunting and from zoo monkeys, originating from different parts of Hungary. F. tularensis strains were isolated from tissue samples on modified Francis agar (chocolate agar plate containing 1% glucose and 0.1% cysteine) after mouse passage. In brief, the homogenized tissue samples were injected subcutaneously into NMRI mouse and at 7 -10 days post-infection, heart blood and bone marrow samples were inoculated on to culture media. Strains were identified with the MicroLog MicroStation System, GN2 MicroPlate (both from Biolog Inc., Hayward, CA, USA) and with a 16S rRNA gene-based PCR method, as described previously. 2 The strains were also phylogenetically characterized using canonical single nucleotide polymorphism assays as described previously, placing the strains into a global phylogeographical framework. 10, 11 Antibiotic susceptibility tests
The susceptibility of F. tularensis strains to 11 antibiotics (erythromycin, streptomycin, gentamicin, ciprofloxacin, levofloxacin, tetracycline, doxycycline, tigecycline, rifampicin, linezolid and chloramphenicol) was determined with MIC test strips (Liofilchem s.r.l., Roseto degli Abruzzi, Italy) on 5 mmthick modified Francis agar plates. The strains were cultured for 48 h on modified Francis agar at 378C in a 5% CO 2 atmosphere. Three to four colonies were suspended in 3 mL of physiological saline, with the turbidity adjusted to be equivalent to that of a 0.5 McFarland standard. The plates were inoculated using sterile cotton swabs and one MIC test strip was placed on each plate within 15 min. After 48 h of incubation at 378C in a 5% CO 2 atmosphere, the MIC results were read according to the manufacturer's instructions. The F. tularensis subsp. holarctica live vaccine strain [LVS (NCTC 10857)] was included as a quality control. The breakpoints were interpreted according to CLSI standards for F. tularensis, where available, and to CLSI standards for Enterobacteriaceae, staphylococci or Streptococcus pneumoniae where specific standards were unavailable. 12 
Results
A collection of 69 F. tularensis subsp. holarctica strains was established and 29 of these strains were systematically chosen for antibiotic susceptibility profile characterization considering their geographical origin, host species and genetic characteristics. Table 1 and Table S1 (available as Supplementary data at JAC Online)].
Discussion
The main aim of this study was to examine the susceptibility of the Hungarian F. tularensis strains to antibiotics with a potential to be used in clinical therapy. As the resistance of F. tularensis subsp. holarctica to b-lactam antibiotics and cephalosporins (with few exceptions) has already been confirmed in several studies, these antibiotics were excluded from the present study. 3 -6,9 Categorization of F. tularensis subsp. holarctica strains based on erythromycin resistance produces two biovars, where biovar I is erythromycin sensitive (present in Western Europe: France, Germany, Spain and Switzerland) while biovar II is resistant (present in Northern and Eastern Europe: Austria, Germany, Sweden and Turkey). 4, 9, 13 All Hungarian strains proved to be consistently resistant to erythromycin, thus confirming their classification into biovar II.
Although linezolid is used in the treatment of infections caused by Gram-positive bacteria, and it is especially active against vancomycin-resistant enterococci and methicillinresistant Staphylococcus aureus, the in vitro susceptibility of F. tularensis to linezolid was also demonstrated in a recent Turkish study. 9 Contrary to the results of the Turkish study, all Hungarian F. tularensis strains were resistant to linezolid, similarly to North American F. tularensis subsp. holarctica strains, with MIC values generally at the breakpoint of resistance. 14 In the treatment of human tularaemia infections, the aminoglycosides gentamicin and streptomycin are the antibiotics of choice in Hungary. 15 All strains were susceptible in vitro to both antibiotics, but it should be noted that in one case (the strain from the patas monkey) the MIC value for streptomycin reached the limit of intermediate susceptibility (8 mg/L).
In 2011, the National Centre of Epidemiology (Budapest, Hungary) recommended ciprofloxacin and chloramphenicol for post-exposure prophylaxis of tularaemia. 15 The examined F. tularensis strains showed high susceptibility to quinolones (ciprofloxacin and levofloxacin) and chloramphenicol as well, although the latter has serious side effects; thus, its use in therapy is limited to exceptional cases (e.g. tularaemia with meningitis). 6, 9 The WHO's guidelines on tularaemia also recommend tetracyclines and especially doxycycline for the therapy of tularaemia. 1 The examined strains showed good in vitro susceptibility to both tetracycline and doxycycline; however, the risk of relapse should be considered during the clinical use of these antibiotics. F. tularensis susceptibility to tigecycline was detected for the first time in the above-mentioned research in Turkey. 9 Tigecycline is a member of the glycylcyclines, a new class of antibiotics that achieves high intracellular concentrations; hence, its use in the treatment of tularaemia has also been recommended. 9 Examining the Hungarian strains' susceptibility to tigecycline, the results were consistent with the susceptibility reported in the publication of Yesilyurt et al. 9 Due to the low in vitro MIC values of tigecycline, this antibiotic may have potential in the clinical therapy of tularaemia in Hungary as well.
Rifampicin was also effective in vitro against the F. tularensis strains, but due to its tendency for emerging resistance in monotherapy, its use is only recommended in combination with other antibiotics (e.g. tetracyclines). 5, 6, 9 In conclusion, on the basis of in vitro examinations, quinolones are recommended as first choice in the therapy of Antimicrobial susceptibility of Hungarian Francisella tularensis strains 371 JAC tularaemia, but aminoglycosides, tetracyclines and chloramphenicol could also be safely used against F. tularensis. The in vitro effectiveness of tigecycline against F. tularensis subsp. holarctica suggests the applicability of this antibiotic in tularaemia treatment as well, but further in vivo examinations are required for confirmation. The use of macrolides (e.g. erythromycin) and linezolid in the treatment of tularaemia should be avoided in Hungary.
Since F. tularensis is a highly clonal bacterium, it inherits DNA in a vertical manner and does not transfer DNA laterally between cells. 10, 11 The coherent antibiotic susceptibilities of the examined strains affiliated to different subclades of one phylogenetic group (B.13) suggests that other strains of the same group from Central and Eastern Europe may react similarly to these antibiotics. 
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